GSK, HGS lupus drug wins green light in Europe

(Reuters) - The first new treatment for lupus in a half-century was recommended for approval in Europe on Friday, offering a new option for patients and underpinning multibillion-dollar sales expectations for its makers.

The companies said the European Medicines Agency had backed use of Benlysta, discovered by Human Genome Sciences and developed with GlaxoSmithKline, to combat the disease that causes the immune system to attack joints and organs.